Parkinson disease

About this disease

A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.

Standard definition source：MONDO:0005180 Parkinson disease · ontology version 2026-10-06

References

1. Shen Zhiqiang, Ma Linlin, Mellick George D., Perše Martina. Strategies for Optimizing Genetic Mouse Models to Enhance the Understanding of Parkinson’s Disease. Biomedicines. 2026.
2. Zambetta Mariana Lara, Fernandes Elayne Borges, Kim Allison, Russo Thiago Luiz, Gianlorenço Anna Carolyna, Prokai-Tatrai Katalin, Kalinderi Kallirhoe. Preclinical Parkinson’s Disease Models for Non-Motor Symptoms: Research Recommendations from a Systematic Review. Life. 2025.
3. Lau Kristina, Outeiro Tiago F, Richter Franziska. Rodent models and accompanying in vitro strategies for studying the etiology and therapy of Parkinson's disease. Journal of Parkinson's Disease. 2026.
4. Kin Kyohei, Yasuhara Takao, Kameda Masahiro, Date Isao. Animal Models for Parkinson’s Disease Research: Trends in the 2000s. International Journal of Molecular Sciences. 2019.
5. Ugalde Valentina, Elgueta Daniela, Espinoza Sandra, Chovar-Vera Ornella, López Ernesto, Catenaccio Alejandra, Álvarez-Astudillo Francisca, Franz Dafne, Sanchez-Guajardo Vanesa, Becker María Inés, Figueroa Diego, Manjarres Zulmary, Hidalgo Sofía, Lladser Álvaro, Tapia-Rojas Cheril, Loyola Alejandra, Quezada Sergio A., Villagra Roque, Pacheco Rodrigo. Preclinical evaluation of nitrated α-synuclein-specific CAR-Treg therapy in Parkinson’s disease. Cell Reports Medicine. 2026.
6. Creed Rose B., Goldberg Matthew S.. New Developments in Genetic Rat Models of Parkinson’s Disease. Movement disorders : official journal of the Movement Disorder Society. 2018.
7. García‐Swinburn Roberto, Morón‐Márquez Laura, Conde‐Naranjo Carmen, García‐Roldán Ernesto, Espadas Isabel, Rodríguez‐Gil Alfonso, Ramírez‐Lorca Reposo, Villadiego Javier, Toledo‐Aral Juan José. Neuroinflammatory and Motor Alterations in LRRK2 * G2019S Transgenic Mice Without Enhanced Vulnerability to Aging or Chronic MPTP ‐Induced Nigrostriatal Neurodegeneration. Journal of Neurochemistry. 2026.
8. Langston J. William. The MPTP Story. Journal of Parkinson's Disease. 2017.
9. Giráldez-Pérez Rosa María, Antolín-Vallespín Mónica, Muñoz María Dolores, Sánchez-Capelo Amelia. Models of α-synuclein aggregation in Parkinson’s disease. Acta Neuropathologica Communications. 2014.
10. Peng Jin, Wang Ziyu, Liu Yu, Wang Xiaohui. Striatal temporal interference stimulation alleviates motor deficits and confers neuroprotection in an MPTP-induced mouse model of Parkinson’s disease with associated improvements in mitochondrial homeostasis. Neurotherapeutics. 2026.
11. Akanchise Thelma, Luo Fucen, Angelov Borislav, Deng Yuru, Fujino Takehiko, Angelova Angelina. Peptide-targeted cubosome and hexosome nanoassemblies mitigate mitochondrial dysfunction in a MitoPark model. Signal Transduction and Targeted Therapy. 2026.
12. Riaz Saima, Ali Shaukat, Summer Muhammad, Iqbal Amina, Ashraf Rimsha, Bibi Ramzana. Chronic Paraquat Neurotoxicity and Dopaminergic Degeneration: A Mechanistic Review. Chemistry & Biodiversity. 2026.
13. Chia Shyh Jenn, Tan Eng-King, Chao Yin-Xia. Historical Perspective: Models of Parkinson’s Disease. International Journal of Molecular Sciences. 2020.
14. Peshattiwar Vaibhavi, Swain Caroline, Pokharel Dipesh, Le Khoi, Kennedy Isabel, Venkiteswaran Kala, Subramanian Thyagarajan. A novel rat model of body first subtype of Parkinson’s disease. bioRxiv. 2026.
15. Mao Mingyu, Wang Yan, Deng Qing, Xiang Jun, Li Wentao. Striatal small RNA remodeling in MPTP-induced Parkinson’s disease highlights coordinated downregulation of mitochondrial tsRNAs. Frontiers in Aging Neuroscience. 2026.
16. Chen Chuyu, He Qianzi, Tombesi Giulia, Napier Eve, Jaconelli Matthew, Moreno-Ramos Oscar Andrés, Serio Hannah, Naaldijk Yahaira, Promes Vanessa, Schneeweis Amanda, Quinn Kaitlyn, Nasios Christopher, Greggio Elisa, Kozorovitskiy Yevgenia, Arango Daniel, Khan Amir R., Alessi Dario R., Dombeck Daniel A., Hilfiker Sabine, Awatramani Rajeshwar, Parisiadou Loukia. Leucine-rich repeat kinase 2 impairs the release sites of Parkinson’s disease vulnerable dopamine axons. Nature Communications. 2026.
17. Apetz Nadine, Kordys Elena, Simon Mascha, Mang Britta, Aswendt Markus, Wiedermann Dirk, Neumaier Bernd, Drzezga Alexander, Timmermann Lars, Endepols Heike. Effects of subthalamic deep brain stimulation on striatal metabolic connectivity in a rat hemiparkinsonian model. Disease Models & Mechanisms. 2019.
18. Kim Jeongah, Choe Mijeong, Jang Sangwon, Park Inah, Oh Sungjoon, Kim Eun-Kyoung, Choe Youngshik, Sun Woong, Kim Kyungjin. Pharmacological inhibition of REV-ERBα ameliorates motor deficits in the 6-OHDA-lesioned mouse model of Parkinson’s disease. Animal Cells and Systems. 2026.
19. Shu Zhan, Lam Hoa A., Videlock Elizabeth J., Lindberg Iris, Maidment Nigel T.. ProSAAS overexpression arrests progression of motor deficits in a rat alpha-synuclein model of Parkinson’s disease. Translational Neurodegeneration. 2026.
20. Araújo-Monteiro Luan, Soares-Silva Beatriz, Carvalhinho-Lopes Patrícia Santos, Moreira Valéria Cunha, de Campos Cruz Binatto Barbara Vitória, Pereira Ellen Games Jacob, de Lima Ana Paula Nascimento, Quintans-Junior Lucindo José, dos Santos José Ronaldo, Ribeiro Alessandra Mussi. β-Cyclodextrin-Complexed 1,8-Cineole Attenuates Motor Deficits and Preserves Tyrosine Hydroxylase Immunoreactivity in a Reserpine-Induced Mouse Model of Parkinsonism. Molecular Neurobiology. 2026.